Seizure types

Global Epilepsy Disease Insights and Market Forecasts Report 2020-2026: Briviact, Vimpat, Depacon, Keppra, Lamictal, Ganaxolone, & Aptiom - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 20, 2021
General Health, Pharmaceutical, Health, Epilepsy, Seizure types

b'The "Epilepsy - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com\'s offering.\n"Epilepsy: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Epilepsy disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Epilepsy, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.\nThis section of the report gives the overview of Epilepsy disease indication in detail.

Key Points: 
  • b'The "Epilepsy - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com\'s offering.\n"Epilepsy: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Epilepsy disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Epilepsy, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.\nThis section of the report gives the overview of Epilepsy disease indication in detail.
  • The section highlights the basic definition, causes and symptoms of disease and details the types of Epilepsy disease.
  • Further details on the profile of Epilepsy patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report.
  • The forecasts are developed based on the detailed drug attribute analysis, as shared in the previous section.\n'

Global Epileptic Seizures Treatment Market to Surpass US$ 4.5 Billion by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Wednesday, January 27, 2021
Pharmaceutical, Health, Other Health, Epilepsy, Medicine, Clinical medicine, Branches of biology, Seizure, Neurological disorders, Seizure types, Neonatal seizure

According to Coherent Market Insights, the global epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).
  • Manufacturers in the epileptic seizures treatment market are continuously focusing on investing in R&D of new drugs to meet demand for effective medications for treating epilepsy, which is expected to drive growth of the epileptic seizures treatment market over the forecast period.
  • The increasing collaborations, partnerships, and agreements between the major players for developing more advanced drugs for epileptic seizures treatment is expected to accelerate the epileptic seizures treatment market growth.
  • The global epileptic seizures treatment market is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027), owing to the increasing product approvals and launches for epileptic seizures treatment.

Global Status Epilepticus Market to 2029 - Growth, Trends, Competitive Landscape, Patient and Forecast - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 10, 2020
Health, Other Health, Medical emergencies, Seizure types, Clinical medicine, Medicine, Status epilepticus, Health, Seizure, Epilepsy, Sé

The "Global Status Epilepticus (SE)-Growth, Trends, Competitive Landscape, Patient and Market Forecast-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Status Epilepticus (SE)-Growth, Trends, Competitive Landscape, Patient and Market Forecast-2029" report has been added to ResearchAndMarkets.com's offering.
  • This report titled offers strategic insights into the global SE market along with the market size and estimates for the duration 2018 to 2029.
  • Status epilepticus is defined as persistent or recurrent seizures due to a failure of seizure termination mechanisms.
  • The seven major incidence of Status Epilepticus (SE) is expected to grow at a CAGR of around 0.58% during 2018-2029.

UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Retrieved on: 
Tuesday, November 17, 2020
Anticonvulsants, Neurological disorders, Chemical compounds, Clinical medicine, Generalized tonic–clonic seizure, Generalized epilepsy, Idiopathic generalized epilepsy, Seizure, Lacosamide, Epilepsy, Lamotrigine, Seizure types

"We are pleased that VIMPAT is now available as a treatment option for people living with primary generalized tonic-clonic seizures on their journey to seizure control."

Key Points: 
  • "We are pleased that VIMPAT is now available as a treatment option for people living with primary generalized tonic-clonic seizures on their journey to seizure control."
  • Results from the Phase 3 study showed that VIMPAT was generally tolerated in patients with Idiopathic Generalized Epilepsy (IGE) and PGTCS.
  • Regarding the expanded pediatric population, VIMPAT tablets and oral solution were already approved to treat partial-onset seizures in adults and children four years and older as monotherapy and adjunctive therapy.
  • VIMPAT injection was previously approved for the treatment of partial-onset seizures only in adult patients (17 years of age and older).

New Coalition Launches to Promote Importance of Seizure Emergency Plans

Retrieved on: 
Sunday, November 1, 2020
Epilepsy, Epileptic seizure, Epilepsy in animals, Medicine, Clinical medicine, Health, Generalized tonic–clonic seizure, Seizure types

WASHINGTON, Nov. 1, 2020 /PRNewswire/ --Today in concert with Epilepsy Awareness Month, a collaboration of three non-profit organizations announced the launch of the Seizure Action Plan (SAP) Coalition to educate people with epilepsy, their caregivers and healthcare professionals about seizure emergency rescue protocols and the importance of personalized seizure action plans.

Key Points: 
  • WASHINGTON, Nov. 1, 2020 /PRNewswire/ --Today in concert with Epilepsy Awareness Month, a collaboration of three non-profit organizations announced the launch of the Seizure Action Plan (SAP) Coalition to educate people with epilepsy, their caregivers and healthcare professionals about seizure emergency rescue protocols and the importance of personalized seizure action plans.
  • Many patients do not currently have seizureemergency plans and by making them a priority in their healthcare plans, they can help ensure immediate and appropriate action is taken during a seizure emergency.
  • This effort to increase education about seizure emergency plans is critical so every family can be prepared to act quickly to halt seizures that won't stop on their own."
  • "The use of seizure rescue plans is a vital component of managing seizure emergencies.

Lennox-Gastaut Syndrome (LGS) Awareness Day to Kick Off Epilepsy Awareness Month

Retrieved on: 
Thursday, October 29, 2020
Health, Clinical medicine, Medicine, Neurological disorders, Lennox–Gastaut syndrome, Syndromes, LGS, Lennox, Epilepsy, Seizure types, Epilepsy syndromes

On this day, families affected by LGS will come together to increase public awareness of this rare disease and share their stories of hope for the future.

Key Points: 
  • On this day, families affected by LGS will come together to increase public awareness of this rare disease and share their stories of hope for the future.
  • LGS is a severe epilepsy syndrome that starts in very early childhood and leads to abnormal brain development and progressive intellectual disability.
  • This weekend, the LGS Foundation, the leading organization in the world dedicated to Lennox-Gastaut Syndrome, is hosting its signature awareness event for LGS Awareness Day in advance of a month of awareness activities which will occur in Epilepsy Awareness Month.
  • For more information on Lennox-Gastaut Syndrome or LGS Awareness Day, please visit www.lgsfoundation.org
    View original content to download multimedia: http://www.prnewswire.com/news-releases/lennox-gastaut-syndrome-lgs-awar...

Focal Epilepsy Often Overlooked

Retrieved on: 
Tuesday, October 20, 2020
Seizure types, Health, Epilepsy, Clinical medicine, Neurology, Focal seizure, Medicine, Epilepsy Phenome/Genome Project, Epilepsy syndromes

The study, publishing online Oct. 20 in the journal Epilepsia, addressed focal epilepsy, the most common form of this brain disorder.

Key Points: 
  • The study, publishing online Oct. 20 in the journal Epilepsia, addressed focal epilepsy, the most common form of this brain disorder.
  • "Our study highlights how common the early and subtle signs of focal epilepsy are," says study senior investigator Jaqueline A. French, MD, a professor of neurology and director of translational research and clinical trials for epilepsy at NYU Langone Health.
  • The World Health Organization estimates that at least 50 million people worldwide have epilepsy, including the most common focal epilepsy, affecting one in 26 American adults.
  • Researchers believe the impact of earlier diagnosis in focal epilepsy patients goes beyond more timely treatment of patients.

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

Retrieved on: 
Friday, October 16, 2020
Neurological disorders, Health, Clinical medicine, Anticonvulsants, RTT, Epilepsy, Seizure types, Syndromes, Generalized tonic–clonic seizure, Epileptic seizure, Generalized epilepsy, Perampanel

Additionally, results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea on untreated epilepsy patients ages 12 years to 74 years old with partial-onset seizures (with or without secondarily generalized seizures) were submitted as supplementary safety and efficacy data.

Key Points: 
  • Additionally, results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea on untreated epilepsy patients ages 12 years to 74 years old with partial-onset seizures (with or without secondarily generalized seizures) were submitted as supplementary safety and efficacy data.
  • The submission covering partial-onset seizures in pediatric patients was based on the results of a Phase III clinical study (Study 311) of Fycompa as adjunctive therapy conducted globally on pediatric patients (ages 4 to less than 12 years) with inadequately controlled partial-onset seizures or primary generalized tonic-clonic seizures.
  • As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs1, this is a disease with significant unmet medical needs.
  • Fycompa has been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.

FDA approves new treatment for adults with partial-onset seizures

Retrieved on: 
Thursday, November 21, 2019
RTT, Anticonvulsants, Epileptic seizure, Clinical medicine, Epilepsy, Medicine, Health, GABAA receptor positive allosteric modulators, Lacosamide, Seizure types

SILVER SPRING, Md., Nov. 21, 2019 /PRNewswire/ --The U.S. Food and Drug Administration today approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults.

Key Points: 
  • SILVER SPRING, Md., Nov. 21, 2019 /PRNewswire/ --The U.S. Food and Drug Administration today approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults.
  • This approval provides an additional needed treatment option for people with this condition."
  • Seizures can cause uncontrolled movements, abnormal thinking or behavior, and abnormal sensations.
  • The safety and efficacy of XCOPRI to treat partial-onset seizures was established in two randomized, double-blind, placebo-controlled studies that enrolled 655 adults.

Epilepsy Foundation Rolls Out #StaySafeSide to Promote Seizure First Aid

Retrieved on: 
Monday, October 21, 2019
Health, Medicine, Clinical medicine, Epileptic seizure, Seizure types, Epilepsy

LANDOVER, Md., Oct. 21, 2019 /PRNewswire/ -- November is National Epilepsy Awareness Month and the Foundation is rolling out #StaySafeSide, a nationwide effort to highlight the importance of recognizing a seizure and promote seizure first aid.

Key Points: 
  • LANDOVER, Md., Oct. 21, 2019 /PRNewswire/ -- November is National Epilepsy Awareness Month and the Foundation is rolling out #StaySafeSide, a nationwide effort to highlight the importance of recognizing a seizure and promote seizure first aid.
  • "While we promote awareness throughout the year, this initiative comes at a time when more education is needed to increase public knowledge about epilepsy and seizure first aid," said Philip M. Gattone, M.Ed., president and CEO of the Epilepsy Foundation.
  • That's why, this November, we challenge everyone to join our National Epilepsy Awareness Month efforts to end epilepsy by learning seizure first aid and educating others in their community."
  • With a network of nearly 50 partners throughout the United States, the Epilepsy Foundation is leading the fight to END EPILEPSY.